Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-03-2014 | Original Paper

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)

Authors: Pierre-Michel Llorca, Christophe Lancon, Olivier Blanc, Ingrid de Chazeron, Ludovic Samalin, Hervé Caci, Jean-Alexandre Lesturgeon, Franck J. Bayle

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2014

Abstract

Anxiety in schizophrenia possesses specific features and is difficult to assess because no specific evaluating tool is currently available. The aim of this study was to develop and validate a hetero-assessment-based scale to specifically measure anxiety in schizophrenia. A literature review and a survey among psychiatrists allowed the selection of 29 items from 4 previous scales evaluating anxiety. Factor analysis allowed building up a final 22-item composite scale of anxiety evaluation in schizophrenia (SAES), which was then validated in 147 schizophrenic patients. One hundred and forty-seven (147) schizophrenic patients (70.8 % male, mean age = 36.9 years) were included in the study. Principal component analysis of the SAES revealed three factors, namely “expressed and perceived anxiety,” “somatic anxiety,” and “anxiety and environment”. All total and factor scores of the SAES were significantly correlated (p < .001) with total and factor scores of the original scales. Finally, the SAES showed good inter-rater reliability [intra-class correlation coefficient (ICC) = .82]. In conclusion, a specific tool for evaluating anxiety in schizophrenia (SAES) was developed and validated in a sample of schizophrenic patients. The SAES can be useful to investigate clinical, psychopathological, and therapeutic aspects of anxiety in schizophrenia.

Achim AM, Maziade M, Raymond É et al (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37:811–821PubMedCrossRef

Bailly D, Viellard M, Duverger H et al (2003) Un diagnostic méconnu: la schizophrénie chez l’enfant. Ann Méd Psychol 161:652–659

Baylé FJ, Llorca PM, Olié JP et al (2000) Anxiété et schizophrénie : situation actuelle. Ann Méd Psychol 158:741–749

Llorca PM (2004) La schizophrénie. In: Leboyer M, Morselli PL (eds) Encyclopédie orphanet. Inserm, Paris

Bogren M, Mattisson C, Tambs K et al (2010) Predictors of psychosis: a 50-year follow-up of the Lundby population. Eur Arch Psychiatry Clin Neurosci 260:113–125PubMedCrossRef

Muller N (2004) Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 37(Suppl. 2):S141–S147PubMedCrossRef

Nuechterlein KH, Miklowitz DJ, Ventura J et al (2006) Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. Psychiatry Res 144:153–166PubMedCrossRef

Pallanti S, Quercioli L, Hollander E (2004) Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 161:53–58PubMedCrossRef

Picardi A, Rucci P, Girolamo G et al (2006) The quality of life of the mentally ill living in residential facilities. Eur Arch Psychiatry Clin Neurosci 256:372–381PubMedCrossRef

10.

Lecardeur L, Stip E, Giguere M et al (2009) Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. Schizophr Res 111:153–158PubMedCrossRef

11.

Steel C, Wykes T, Ruddle A et al (2010) Can we harness computerised cognitive bias modification to treat anxiety in schizophrenia? A first step highlighting the role of mental imagery. Psychiatry Res 178:451–455PubMedCrossRef

12.

Tsai J, Lysaker PH, Vohs JL (2010) Negative symptoms and concomitant attention deficits in schizophrenia: associations with prospective assessments of anxiety, social dysfunction, and avoidant coping. J Ment Health 19:184–192PubMedCentralPubMedCrossRef

13.

Morrison JM, Myhr G (2010) Theory of mind and global empathy performance in schizophrenia: the role of anxiety, remission status and symptom type. Schizophr Res 117:327CrossRef

14.

Lysaker PH, Yanos PT, Outcalt J et al (2010) Association of stigma, self-esteem, and symptoms with concurrent and prospective assessment of social anxiety in schizophrenia. Clin Schizophr Relat Psychoses 4:41–48PubMedCentralPubMedCrossRef

15.

Braga RJ, Petrides G, Figueira I (2004) Anxiety disorders in schizophrenia. Comp Psychiatry 45:460–468CrossRef

16.

Braga RJ, Mendlowicz MV, Marrocos RP et al (2005) Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatric Res 39:409–414CrossRef

17.

Huppert JD, Smith TE (2001) Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 189:669–675PubMedCrossRef

18.

Huppert JD, Weiss KA, Lim R et al (2001) Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 51:171–180PubMedCrossRef

19.

Lysaker PH, Salvatore G, Grant MLA et al (2010) Deficits in theory of mind and social anxiety as independent paths to paranoid features in schizophrenia. Schizophr Res 124:81–85PubMedCrossRef

20.

Allilaire JF (1983) Angoisse psychotique et angoisse névrotique. Différence qualitative ou différence quantitative? L’Encéphale 9(suppl. 2):211B–216BPubMed

21.

Cutler JL, Siris SG (1991) “Panic-like” symptomatology in schizophrenic and schizoaffective patients with postpsychotic depression: observations and implications. Comp Psychiatry 32:465–473CrossRef

22.

Baylé FJ, Blanc O, De Chazeron I et al (2011) Prise en charge médicamenteuse de l’anxiété chez le patient souffrant de schizophrénie. L’Encéphale 37(Supplement 1):S83–S89PubMedCrossRef

23.

Blin O, Azorin JM, Lecrubier Y et al (1989) Psychotic anxiety scale (PAS): évaluation de la fidélité intercotateurs et analyse factorielle des correspondances. L’Encéphale 15:543–547PubMed

24.

Romain JL, Dermain P, Greslé P et al (1996) Efficacité de l’acétate de zuclopenthixol sur l’anxiété psychotique évaluée lors d’une étude ouverte. L’Encéphale 22:280–286PubMed

25.

Blin O, Azorin JM, Bouhours P (1996) Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 16:38–44PubMedCrossRef

26.

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRef

27.

Tyrer P, Owen RT, Cicchetti DV (1984) The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry 47:970–975PubMedCrossRef

28.

Guy W, Ban TA (1982) The AMDP-System. Manual for the assessment and documentation of psychopathology. Springer, Berlin Heidelberg

29.

Asberg M, Montgomery SA, Perris C et al (1978) A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica Suppl. 271:5–27CrossRef

30.

Guelfi JD, Waintraub L, Fermanian J et al (1987) La version française de la CPRS: analyse factorielle sur un échantillon de 208 patients. L’Encéphale 2:395–400

31.

Pichot P, Pull CB, von Frenckell R et al. (1981) Une analyse factorielle de l’échelle d’appréciation de l’anxiété de Hamilton. Psychiat Fennica:183–189

32.

Lesur A, Bonnet D, Vicaut E et al (1989) L’échelle brève d’anxiété de Tyrer en pratique extrahospitalière: première validation en langue française. L’ Encéphale 15:535–542

33.

Bobon D, von Frenckell R, Troisfontaines B et al (1985) Preliminary construction and validation of an anxiety scale derived from the French version of the AMDP, the AMDP-AT. Encephale 11:107–111PubMed

34.

Likert R (1932) A technique for the measurement of attitudes. Archives Psychol 140:5–55

35.

Bowles N (1999) The Delphi technique. Nurs Standard 13:32–36CrossRef

36.

Lançon C, Aghababian C, Llorca P-M BD, Auquier P (1999) An exploration of the psychometric properties of the French-language version of the positive and negative syndrome scale (PANSS). Can J Psychiatry 44:893–900PubMed

37.

Kaiser HF (1974) An index of factorial simplicity. Psychometrika 39:31–36CrossRef

38.

Lance CEBM, Michels MC (2006) The sources of four commonly reported cutoff criteria, what did they really say? Organizational Res Meth 9:202–220CrossRef

39.

Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420–428PubMedCrossRef

40.

Kline P (1994) An easy guide to factor analysis. Routledge, London

41.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 13:261–274CrossRef

42.

Huppert JD, Smith TE (2005) Anxiety and schizophrenia: the interaction of subtypes of anxiety and psychotic symptoms. CNS Spectr 10:721–731PubMed

43.

Peuskens J, Van Baelen B, De Smedt C et al (2000) Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15:343–349PubMedCrossRef

44.

Tollefson GD, Sanger TM, Lu Y et al (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250–258PubMedCrossRef

45.

Kinon BJ, Ascher-Svanum H, Adams DH et al (2008) The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J Clin Psychopharmacol 28:544–549PubMedCrossRef

46.

Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 156:610–616PubMed

47.

Dollfus S, Olivier V, Chabot B et al (2005) Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 78:157–159PubMedCrossRef

48.

Kim SW, Shin IS, Kim JM et al (2007) Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31:1504–1509PubMedCrossRef

Title: A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)
Authors: Pierre-Michel Llorca
Christophe Lancon
Olivier Blanc
Ingrid de Chazeron
Ludovic Samalin
Hervé Caci
Jean-Alexandre Lesturgeon
Franck J. Bayle
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2014
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-013-0416-1

2024 ASCO Annual Meeting

Springer Medicine

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Thalamocortical connectivity during resting state in schizophrenia

The new risk variant CACNA1C and brain circuits in schizophrenia

Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate

Neural correlates of semantic associations in patients with schizophrenia

CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia

A genome-wide supported variant in CACNA1C influences hippocampal activation during episodic memory encoding and retrieval